Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

7.2K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.2K
Base Excision Repair01:54

Base Excision Repair

23.0K
One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...
23.0K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

9.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

259
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
259

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Candida growth in urine cultures: a contemporary analysis of species and antifungal susceptibility profiles.

QJM : monthly journal of the Association of Physicians·2015
Same author

A 46 year old man with carcinoma of unknown primary site.

BMJ (Clinical research ed.)·2012
Same author

Another patient with low back pain.

BMJ (Clinical research ed.)·2012
Same author

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same author

Hsp90 inhibitors in the clinic.

Handbook of experimental pharmacology·2006
Same author

Low dose erythropoietin is effective in reducing transfusion requirements following allogeneic HSCT.

Transfusion medicine (Oxford, England)·2005
Same journal

Research Trends in Physical Activity and Breast Cancer: A 25-Year Bibliometric Analysis (2000-2025).

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Concordance Between Planned and Delivered treatment for Head and Neck Cancer Patients Treated With Curative Intent: A Real-World Comparison of Under 70-year-olds With 70-year-olds and Over.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

A Novel Technique for Pain Management to Deliver a Course of Palliative Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Broad-Spectrum Antibiotics are Associated with worse Survival After Radical Treatment for Glioblastoma Multiforme: A Multicentre Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Exploring the Need for Plan Adaptation in Robustly Optimised Head and Neck Intensity Modulated Proton Therapy: A Dosimetric Perspective From Initial Institutional Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

Related Experiment Video

Updated: Sep 17, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.1K

Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects.

A F Palma Dos Reis1, L G Faulkner1, I W Lai2

  • 1Early Cancer Institute, University of Cambridge, United Kingdom.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|June 29, 2025
PubMed
Summary
This summary is machine-generated.

Combining poly(ADP-ribose)polymerase inhibitors (PARPi) with androgen receptor signalling inhibitors (ARSI) shows variable efficacy in prostate cancer (PCa). While BRCA-mutated PCa benefits most, non-homologous repair deficiency (non-HRD) cohorts show controversial results, necessitating further research into optimized treatment strategies.

Keywords:
Androgen receptor signalling pathway inhibitorsBRCADNA damaging agentsDNA repair deficiencyHRHRDPARP inhibitorsnew hormonal agentsprecision medicineprostate cancertargeted treatments

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.4K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.1K

Related Experiment Videos

Last Updated: Sep 17, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.1K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.4K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.1K

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Prostate cancer (PCa) is a leading cause of cancer mortality in Western countries, with limited targeted therapy options, especially post-chemotherapy progression.
  • Targeted therapies offer reduced toxicity, crucial for the elderly PCa patient population.

Purpose of the Study:

  • To review current evidence on combining poly(ADP-ribose)polymerase inhibitors (PARPi) with androgen receptor signalling inhibitors (ARSI) for prostate cancer (PCa).
  • To explore the potential of these combinations beyond patients with established DNA repair deficiencies.
  • To inform future research and clinical practice in PCa treatment.

Main Methods:

  • Comprehensive literature review of publications indexed in PubMed, EMBASE, and Medline.
  • Focus on prostate cancer genetics, PARPi mechanisms, and pre-clinical/clinical data.
  • Analysis of PARPi and ARSI combination therapy outcomes.

Main Results:

  • PARPi/ARSI combinations yield variable responses in prostate cancer (PCa).
  • BRCA-mutated PCa shows consistent positive outcomes.
  • PCa with other homologous repair defects (HRD) demonstrates lesser benefits, and efficacy in non-HRD cohorts remains debated.

Conclusions:

  • The therapeutic benefits of PARPi/ARSI combinations must be balanced against increased toxicity.
  • Future research should prioritize developing tolerable PARPi, optimizing combination strategies, and refining diagnostic tools for DNA repair deficiencies.
  • Identifying molecular drivers of PARPi response in PCa is crucial for personalized treatment.